Primary Antibiotic Prophylaxis Using Co-trimoxazole to Prevent Spontaneous Bacterial Peritonitis in Cirrhosis

Who is this study for? Patients with liver cirrhosis
What treatments are being studied? Co-Trimoxazole
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

A multicentre, interventional, double-blind, placebo-controlled, parallel-arm, phase 3, randomised controlled trial to evaluate the use of co-trimoxazole as primary prophylaxis for spontaneous bacterial peritonitis to improve overall survival

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: No
View:

• Patients with Child-Pugh Class B or C cirrhosis and presence of ascites requiring any diuretic treatment or at least 1 or more paracentesis within 3 months prior to enrolment.

• Patient at least 18 years of age

• Documented informed consent to participate

Locations
Other Locations
United Kingdom
Royal Free hospital
Recruiting
Hampstead
Contact Information
Primary
David Gear
david.gear.16@ucl.ac.uk
02076705748
Backup
Marisa Chau
m.chau@ucl.ac.uk
Time Frame
Start Date: June 30, 2019
Estimated Completion Date: October 2024
Participants
Target number of participants: 432
Treatments
Experimental: Co-trimoxazole
Co-trimoxazole, 960mg capsule oral tablet, to be taken daily for 18 months
Placebo Comparator: Placebo
Placebo, 960mg capsule oral tablet, to be taken daily for 18 months
Sponsors
Collaborators: National Institute for Health Research, United Kingdom
Leads: University College, London

This content was sourced from clinicaltrials.gov

Similar Clinical Trials